Biotie Therapies - Major shareholder announcements

Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE July 23, 2009, at 1:15
p.m.


Notification according to Chapter 2, Section 10 of the Finnish
Securities Market Act

Biotie Therapies Corp. ("the Company" or "Biotie") has on July 22,
2009 gained knowledge of the notifications regarding the following
changes in holdings in accordance with Chapter 2, Section 9 of the
Finnish Securities Markets Act.

Elbion NV, Biotie's current largest shareholder, has notified the
Company that as a result of a series of share transactions carried
out on July 20, 2009, the holdings of elbion NV in the Company have
decreased from above 31.20% to below 5%. As a consequence, elbion NV
has no longer the obligation to make a public tender offer in
accordance with Chapter 6, Section 10 of the Finnish Securities
Markets Act. In November 2008, elbion NV was granted an exemption
from the obligation to make such a public tender offer for all the
Biotie shares even though its holdings exceeded 3/10 of the voting
rights attached to all shares of the Company. The originally granted
exemption provided for a reduction of the elbion NV voting rights in
Biotie referred to in Chapter 6, Section 10 of the Finnish Securities
Markets Act to or below 3/10 within nine months from the date the
Shares issued to elbion NV in connection with the Exchange Offer had
been entered into the Trade Register.

Moreover, TVM Life Science Ventures VI GmbH & Co. KG and Burrill &
Company LLC have notified the Company that as a result of these share
transactions carried out on July 20, 2009, the aggregate holdings of
these shareholders have increased to above 10% and 5% respectively.

The changes in holdings in accordance with Chapter 2, Section 9 of
the Finnish Securities Markets Act of which the Company has gained
knowledge are described below.


Name of the shareholder                  Shares % of shares after the
                                      after the          transactions
                                   transactions

elbion NV                             1,351,613                   0.9

TVM Life Science Ventures VI GmbH    15,302,500                  10.6& Co. KG
(HRA 84941)
Funds managed by Burrill & Company   10,412,744                   7.2
LLC.



The registered number of shares in Biotie Therapies Corp. is
144,320,560 and the number of voting rights attached to the shares
amounts to 144,320,560.

Turku, July 23, 2009

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media